Bristol-Myers Squibb Co. has announced it will acquire Amylin Pharmaceuticals for approximately US $5.3 billion in cash. Following the completion of this acquisition, Bristol-Myers Squibb will ...
The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...
Monthly production output was estimated to have decreased by 0.4% in November 2024; this is the third consecutive monthly fall after decreases of 0.3% and 0.6% in September 2024 and October 2024, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback